The company sells its consumer-targeted simple DNA kits online. A DNA-code customer sample is sent back to the company, while one may receive the information drawn from the analysis of their genetic material via the company?s online platform. The main idea relies on the discovery of one?s family connections and the possibility of contacting their relatives. However, 23andMe could not inform its customers of any disease-related risks in the past ? apparently, the situation has changed now.
U.S. Food and Drug Administration (FDA) has given its permission to that the company may start providing its customers with more data drawn from samples such received, more specifically meant as informing them of the risk of being subject to the occurence of serious diseases in them. Currently, there exists the possibility of having the following 10 diseases recognised: Parkinson?s disease, Alzheimer?s disease, intolerance to gluten, Aplha-1 antitrypsin deficiency, primary dystonia, blond coagulation disorders, Gaucher disease type 1, enzyme glucose 6-phosphate dehydrogenase deficiency, hemochromatosis, thrombophilia.
?FDA have approved our innovations, thus entitling our customers to receive direct information on disease risks?, underlines Anne Wojcicki, the representative of 23andMe. ?It is a very important step for our company and the development of personal genomics?, she adds.
23andMe is the first company to have produced commonly available and FDA-approved DNA tests for consumers. The information they provide will not include any diagnoses of diseases but will only serve as the determination of risk of the occurence of a given entity. In the nearest future, the company is planning to increase the recognition of chronic diseases from 10 to 254.